The molecular design of and challenges relating to sensitizers for cancer sonodynamic therapy

Yiming Zhou, Mengxuan Wang and Zhifei Dai* 

Sonodynamic therapy is a promising non-invasive treatment approach against malignant tumors. It is believed that sonodynamic therapy is advantageous over conventional photodynamic therapy due to its better penetration abilities. However, the efficacy of sonodynamic therapy is limited by the poor reactive oxygen species generation abilities of current sonosensitizers. To fulfill the unreleased potential of sonodynamic therapy, it is reasonable to optimize the properties of the sonosensitizers according to the basic mechanism of sonodynamic therapy. Here, in this review, the most recent research progress relating to the mechanism of sonodynamic therapy will be emphasized and a series of possible principles for the design of effective sonosensitizers will be proposed. Further challenges relating to the clinical translation of sonodynamic therapy will also be discussed to give a clear picture of the problems that must be overcome.

Introduction

Clinical cancer treatment modalities including surgery, chemotherapy and radiotherapy are invasive, non-specific or use radiation.1–5 To increase therapeutic efficacy and reduce adverse effects, non-invasive therapy6 has become an optional choice in treating patients with mild cases or advanced cases that other therapies have failed to treat. Sonodynamic therapy (SDT) has become an emerging non-invasive therapeutic modality for tumor therapy in recent years.7 Similar to the clinically used photodynamic therapy (PDT), sonodynamic therapy applies low intensity focused ultrasound (LIFU) to excite sonosensitizers to generate reactive oxygen species (ROS), which are toxic to tumor cells.8 SDT is advantageous over PDT in several aspects.

The efficacy of PDT is hindered by the weak penetration ability of visible light, meaning that only tumor cells receiving light will be damaged whilst others will not be ablated.9 In spite of the development of photosensitizers (PSs) with longer excitation wavelengths,10 near-infrared light can only reach the tissue within several centimeters below the skin.11 As a result, it is not certain whether the light could fully cover the primary tumor or even reach superficial metastases during treatment. Besides, PDT has limitations treating deep tumors such as hepatic carcinoma, renal carcinoma and glioma12 non-invasively.
Another “Achilles’ heel” of PDT is the phototoxicity of photosensitizers, which is attributed to the systematic distribution of PSs. Patients have to avoid direct exposure to light both before and after treatment as visible light could damage healthy skin containing accumulated photosensitizers. However, as a routinely applied imaging modality in clinic, ultrasound imaging is capable of monitoring every parenchymal organ. The penetration ability of ultrasound can be tuned by the modulation of ultrasound frequency and the intensity can be simply regulated with an amplifier. Therefore, SDT can be applied in the treatment of any kind of solid tumor with distinctive depths non-invasively under proper imaging in theory. Unlike PSs, sonosensitizers with high sonosensitivity and low photosensitivity can be rationally designed to reduce their photoactivity. Above all, SDT is a promising non-invasive therapy against tumors, which could be compatible with PDT in the future.

To distinguish SDT from traditional thermal-dependent ultrasound therapy (i.e. high intensity focused ultrasound (HIFU)), sonosensitizers are an indispensable component of SDT but not of HIFU. The targeted accumulation of sonosensitizers in the diseased area is the first step of SDT and the therapeutic effect is predominantly determined by the ROS instead of heat. Sonosensitizers can be defined as molecules that absorb ultrasound energy and excite surrounding oxygen molecules or other molecule substrates to release ROS. The earliest sonosensitizer to be investigated was hematoporphyrin by Yumita et al. in 1989. For the first time they demonstrated that the combination of ultrasound and drug therapy could cause irreversible damage to tumor cells while neither of them decreased the cell viability alone. Sonosensitizers can be chemotherapeutic drugs and the ROS triggered by ultrasound can further enhance the chemotherapy effect. The antitumor drug doxorubicin is a well-known example. However, the majority of sonosensitizers have been derived from photosensitizers used in PDT so far. Adopting clinically approved photosensitizers can be a double-edged sword for SDT. The drugs involved are more likely to be approved but the defects of the PSs have to be tolerated and they might not be as effective as we thought. To optimize the sonosensitizers used in SDT, it is reasonable to de novo design a sonosensitizer according to the mechanism of SDT as well as taking the pharmacokinetics, biodistribution and toxicity into consideration. Ideally, a good sonosensitizer should (i) be of high sonosensitivity, (ii) be non-toxic in the absence of ultrasound, (iii) specifically accumulate in the tumor site and (iv) be excreted from the body within a short period. Nevertheless, few reviews have extensively discussed the design of sonosensitizers as far as we know.

In this review, we will discuss the principles of the molecular design of sonosensitizers on the basis of the mechanism of sonodynamic therapy. By analyzing recent newly developed sonosensitizers, we outlined the major design considerations of sonosensitizers. At last, the challenges in the clinical translation of SDT will be addressed to point out a pathway that might lead to the successful clinical translation of SDT.

The mechanism of SDT

Since the cytotoxicity of SDT was discovered, lots of researchers devoted their work to reveal the mechanism behind it. However, subject to the accuracy and detecting ability of the equipment, part of the proposed mechanism still cannot be verified. Insight into the theory of SDT could provide great help in designing on-demand sonosensitizers. Unlike the wave-particle duality nature of light, ultrasound is a kind of mechanical wave. As a result, the difference in the energy transfer between molecules and stimulators will be discussed first of all. On the other hand, the unique effects (including cavitation and sonoluminescence) caused by ultrasound should not be ignored.

To understand how a sensitizer is triggered by ultrasound, we shall first review how the energy of light is transferred to a photosensitizer during PDT (Fig. 1). The energy (E) of a photon can be calculated using Planck’s constant (h). The following equation gives the relationship between E and the light wavelength λ, where c represents the speed of light.

\[ E = h \times \frac{c}{\lambda} \]

![Professor Zhifei Dai](image_url)

Professor Zhifei Dai obtained his PhD degree at the Technical Institute of Physics and Chemistry, CAS in 1998. He is now a professor at the Department of Biomedical Engineering, Peking University, and a chief scientist for the National Key Research and Development Program of China. Prof. Dai’s research is focused on sophisticated biomaterials and nanotechnology for the development of advanced drug delivery systems, molecular imaging, and the sensing of diseased cells and organs. Prof. Dai is now serving as a vice chairman for the Chinese Society of Biomedical Engineering in Photonics, as an executive member of the council for the Chinese Society for Functional Materials, and as a standing committee member for several organizations.
Upon absorbance of a photon’s energy, an electron of the sensitizer is promoted to a higher singlet energy state ($S_1$) from the ground state ($S_0$). However, when the promoted electrons fall back to a low-energy state, there are two ways to proceed.\textsuperscript{9} First is internal conversion, fluorescence is the outcome of the released energy when the electrons return to $S_0$. Intersystem crossing occurs when the excited electron’s spin state is changed and the triplet excited state ($T_1$) is formed. A type I reaction will happen when the excited sensitizer oxidizes the substrates and the reduced sensitziers can react with oxygen to generate a superoxide ion and other ROS derivates. In the type II reaction, the energy of $T_1$ is transferred to molecular oxygen, promoting it to singlet oxygen, also known as $^1O_2$. Singlet oxygen is highly active but its half-life is short and its travel distance is limited (less than 20 nm).\textsuperscript{32} Usually the type I and type II reactions take place at the same time.

Ultrasound is a kind of mechanical wave with a frequency higher than 20 kHz. To fully describe the properties of ultrasound, acoustic pressure ($p$) and acoustic intensity ($I$) should also be included. The relationship between them is listed as the following equation:

$$p^2 = I \times v \times \rho$$

In the above equation, $v$ represents the velocity of ultrasound in the medium (density = $\rho$). The ultrasound wave emitted from a transducer can be radial or focused based on the type of transducer. In order to describe the energy distribution of the ultrasound, a sound field is introduced, which can be obtained using an automatic moving device carrying a receiver to paint the details of the wave generated from an ultrasound transducer.\textsuperscript{33} From the acoustic field, we can calculate the power of every point through a fitted model.\textsuperscript{34} When we refer to the intensity of the ultrasound, it represents the energy around the focus. There has been no general standard of the power of the LIFU, but the spatial peak time average sound intensity (SPTA) of LIFU used in SDT is usually less than 5 W cm$^{-2}$. The frequency of ultrasound is associated with the penetration depth, the higher the frequency is, the lower the penetration ability is. The reported frequency of SDT is no more than 2 MHz. It should be noted that almost no reported papers about SDT mention the acoustic pressure used. When traveling through a liquid environment or tissue, the ultrasound will induce gas-filled microbubbles to oscillate in the acoustic field.\textsuperscript{28} This process is called cavitation and with the increase of the acoustic pressure, the microbubbles will finally implode. Upon implosion of the microbubbles, lots of heat and sometimes light (sonoluminescence) is released.\textsuperscript{35} The temporary ultrahigh temperature can lead to pyrolysis of the sonosensitizers or water thus generating the ROS\textsuperscript{36} (Fig. 2).

Notably, growing evidence has shown that the emitted light from the non-inertial cavitating bubbles might contribute to the singlet oxygen generation in that the tested sonosensitizers were also photosensitizers.\textsuperscript{38} Here we can point out the relatively exact mechanism of SDT from the known evidence that is when the acoustic intensity of ultrasound is low, sonoluminescence is the key reason for singlet oxygen generation, while when the acoustic intensity is high, hydroxyl radicals are generated as the result of inertial cavitation. Meanwhile, the antiangiogenesis effect of ultrasound and immunity activation induced by the exposure of antigens on the dead tumor cells also contributes to the mechanism of SDT. Table 1 gives a brief summary of the similarities and differences between the PDT and SDT.

### Sonosensitizer design principles

Sonosensitizers can be classified into small molecules and micro/nanoparticles.\textsuperscript{40} Most of the small molecules are existing photosensitzers or approved drugs. Though plenty of published papers exhibited encouraging results about the so-called multifunctional nanoparticles in SDT, few could provide useful insights into the design of sonosensitizers that are promising for clinical use. Here we try to propose a series of design principles of sonosensitizers on the basis of the fundamental principles of drug design and SDT.

### ROS generation ability

The ROS generation ability is highly associated with the inherent properties of molecules. In PDT, a concept named singlet oxygen quantum yield ($\Phi$) is introduced to describe the ability of PSs to generate ROS.\textsuperscript{41} A standard substance with known $\Phi$ is used as a reference\textsuperscript{42} to calculate the $\Phi$ of the measured molecule. Different probes are utilized to quantify and distinguish singlet oxygen and OH hydroxyl radicals during the PDT/SDT. Commonly, researchers use the SOSG to semi-quantify the generation of singlet oxygen\textsuperscript{43} and H$_2$DCF to semi-quantify the general ROS through fluorescence.\textsuperscript{44} $\Phi$ is associated with the chemical structure of the sensitziers. Taking the porphyrin class sensitizer as an example, the $\Phi$ can be affected by the center atom chelated into the porphyrin ring.\textsuperscript{45} Usually the element...
with more than two coordination keys will decrease the $\Phi$ as the ligand might block the interaction between the oxygen molecule and the plane of the porphyrin ring. A similar principle can be applied to the sonosensitizer because oxygen is indispensable during both PDT and SDT.

Besides, to precisely calculate the energy gap of a molecule, the HOMO–LUMO theory has to be introduced to describe the lowest energy needed to excite the molecule to an activated status. The lower the value is, the easier it is for the molecule to be excited by external energy. In a recent research report, Ma et al. synthesized a series of metalloporphyrins chelated with different metal elements. They firstly calculated the HOMO–LUMO plots of MnTTP, TiOTTP and ZnTTP by density functional theory (Fig. 3). Consistent with the simulation results, MnTTP exhibited the highest ROS generation ability and cytotoxicity in vitro in that it had the lowest excited energy. The MnTTP–HSA complex showed excellent in vivo antitumor effects as well.

Another important factor affecting the $\Phi$ is the lipid–water partition coefficient ($\log D$), which quantifies the hydrophilicity and hydrophobicity of a molecule. Molecules with higher hydrophobicity obtain a larger score. Most naturally existing photosensitizers are very hydrophobic, leading to severe aggregation in the body fluid. However, the aggregation state can largely decrease the ROS generated by the sensitizers. Introducing polar groups into the molecules can increase the hydrophilicity of the sensitizers preventing them from forming precipitation in solution but the aromatic rings of porphyrins or phthalocyanines tend to aggregate, forming the H-aggregates. The absorbance peak of the H-aggregates is blue-shifted and the fluorescence is usually quenched. Axial modification is an efficient way to avoid H-aggregates while the synthesis is complex and not all the sensitizers can be modified. Encapsulating the sonosensitizers into the nanoparticles can increase the solubility of the hydrophobic molecules. Nevertheless, the aggregation of sonosensitizers in the nanoparticles and the potential premature release of the inside drug indicate the inherent shortcomings of the nanomedicine. To this end, covalently conjugating the drug onto the nanoparticle surface or inside the mesoporous nanoparticle is a promising way to solve these problems. Anchoring the sonosensitizer molecules onto silica nanoparticles reduced the undesired aggregation and enhanced the therapeutic effect. The chelated manganese in the phorphyrins made the magnetic resonance imaging guided sonodynamic therapy possible. In spite of the extensive evidence showing that mesoporous silica nanoparticles are able to be degraded and excreted from the body within several days, the safety concern of these inorganic nanoparticles could be the biggest obstacles hindering them from being translated into clinical use (Fig. 4).

When the yield of $^{1}O_2$ is limited in the SDT, increasing the hydroxyl radicals can also enhance the SDT effect. Pan and colleagues demonstrated that a metal–organic framework (MOF)-derived carbon nanostructure with a porphyrin-like center had high ROS generation ability under the exposure of ultrasound. The ESR results showed that the significant difference in the ROS generation was attributed to the outstanding hydroxyl radicals’ yield (Fig. 5).

The addition of the external cavitation nucleus is a potential way to enhance the SDT effect by increasing the cavitation effect. TiO$_2$ nanoparticles were found to have an effective ultrasound triggered response. Upon the addition of gold nanoparticles as the cavitation nucleus, the ROS was significantly enhanced when using DPBF as the detection probe.

**Sonosensitizer targeting ability**

Since the term “magic bullet” was proposed more than 100 years ago, much effort has been devoted to realizing accurate drug delivery to a diseased area. The theory includes two aspects, one is to enhance drug accumulation in the lesion and the other is to reduce unwanted nonspecific distribution of the drugs. Attaching a targeting ligand to the drug is believed to be an effective strategy and the exciting pre-clinical results of nanomedicine indicate its great potential for precise drug delivery. However, only several antibody–drug conjugates...
(ADCs) have been successfully translated into clinic\textsuperscript{70} and the promise of nanomedicine is discounted due to its poor clinical outcomes.\textsuperscript{71} Although sonosensitizers are a little bit different from traditional chemo drugs or targeted drugs owing to their mechanism, sonosensitizers with a better targeting ability contribute to enhancement of the SDT effect.

Because of the photoactive nature of most sonosensitizers, the fundamental way to protect patients from side effects and to enhance the therapeutic effect is to avoid unwanted accumulation in other organs. Except for a few small molecules with an inherent targeting ability for tumors,\textsuperscript{72} most porphyrin- or cyanine-based sonosensitizers are not specifically absorbed by tumor cells.\textsuperscript{73} Modifying the small molecules with an antibody or small peptide which can target the receptors overexpressed on the tumor cell surface is a well-adopted strategy.\textsuperscript{74} Many antibodies including bevacizumab, cetuximab and panitumumab that have proved effective in patients are being conjugated with fluorescent dyes and are under clinical trial for imaging guided surgery.\textsuperscript{74} Moreover, the immunophototherapy effects of cetuximab–IRdye700DX conjugate (ASP-1929) has been tested in patients with head and neck cancer, colon cancer, lung cancer and so on.\textsuperscript{75} The conjugates exhibited long circulation times and enhanced uptake by tumors but their penetration into deep tumor cells was inhibited because of the large volume.\textsuperscript{76} Nanobodies are believed to have a better penetration ability because they have a smaller volume as well as compatible targeting ability with the traditional antibody.\textsuperscript{77} However, when it comes to the cost of development, small targeting peptides or small molecules are more accepted than the antibody. Cyclic RGD is a well exploited peptide with great affinity for the integrins on the surface of the neovascularization of tumor cells.\textsuperscript{78} Peptides targeting c-Met have been conjugated with Cy5 for the detection of colon polyps and cancer.\textsuperscript{79} Besides, plenty of folate acid conjugated drug/fluorescent dyes have entered clinical trials for the treatment of ovarian cancer, lung cancer and other folate acid receptor overexpressed tumors.\textsuperscript{80} Besides the targeted small molecules, nanoparticles with active targeting ligands are being extensively explored.\textsuperscript{81} The commonly believed hypothesis was that targeted nanoparticles could directly bind tumor cells, however recent research has overthrown it.\textsuperscript{82} Upon entry of nanoparticles into the blood vessels, the proteins adsorbed determines their final fate.\textsuperscript{83} As a result, the exact mechanism of the so called “active targeting” of nanoparticles is still under debate and more research is needed to further elucidate it. The achievement of the preclinical results of the targeted nanoparticles cannot guarantee its further success. Based on the enormous efforts toward the development of ADCs and peptide–drug conjugates, we can learn lessons from them to increase the targeting ability of sonosensitizers.

The ideal SDT requires selective control of the location of sonosensitizers and ROS generation. A smart off–on mode of sonosensitizers is crucial for the enhancement of SDT. Precise design for the control of photosensitizers for PDT has been summarized somewhere else.\textsuperscript{84} These strategies are helpful for reducing undesired phototoxicity but might not be valuable for the enhancement of SDT effects. Few papers explored the relationship between the molecule status and the corresponding sonosensitivity, so it is still unknown to us now whether ROS generation could be tuned with the molecular status change of the sonosensitizers. A deeper understanding of the mechanism of SDT will help us design smarter sonosensitizers.
Oxygen supply

The tumor microenvironment (TME) can be very hypoxic due to the Warburg effect. Without a sufficient oxygen supply, SDT cannot fulfill its biggest potential and the consumption of oxygen in tumors might exacerbate the hypoxic status thus leading to poor outcomes. To solve these problems, Beguin et al. developed a new kind of oxygen microbubble and the lipid shell was conjugated with sonosensitizer RB (Fig. 6). Moreover, to enhance the accumulation of microbubbles in the tumor site, magnetic lipids were incorporated into the shell to achieve magnet guided local SDT. The in vivo antitumor results proved that the alignment of the ultrasound and the magnet could enhance the therapeutic effect of the oxygen microbubble against pancreatic tumors. The enhanced treatment effect could be attributed to several aspects: (i) the sufficient oxygen supply during the SDT, (ii) microbubble assisted cell membrane disruption and improved drug uptake and (iii) the enhanced cavitation effect by the microbubbles.

Since there has been a long-term investigation on overcoming the absence of sufficient oxygen during PDT, it is reasonable to learn from the experience in the molecular design of sonosensitizers. Adopting a redox reaction between the endogenous or exogenous H\textsubscript{2}O\textsubscript{2} and catalase, all-in-one nanoparticles were designed to enhance the SDT effect by modulating the hypoxic tumor environment (Fig. 7). The incorporation of oxygen carriers can significantly ameliorate hypoxia. As a natural carrier of oxygen, engineered red blood cells loaded with sonosensitizers were able to effectively ablate tumors by relieving the hypoxia. Recently, perfluorocarbon filled nanobubbles carrying the sonosensitizer Ce6 were demonstrated to be able to induce strong anti-tumor immunity in the murine model. The natural oxygen concentration ability of the perfluorocarbon might contribute to the enhancement.

Ultrasound parameters

When SDT is carried out, the cell membrane could be disrupted by the sono-mechanical force, which could enhance the SDT effect. However, there has been a long-standing debate about the cytotoxicity of low intensity focused ultrasound. Recently a research report revealed that low intensity pulsed ultrasound could cause selective ablation of leukemia with little effect on other normal cells such as T cells and red blood cells (Fig. 8). The selective killing also applied for the other solid tumor cell lines both from mice and humans. Further mechanism study revealed the increase of immunogenic cell death markers after ultrasonic treatment. This finding was interesting but specific conditions, including a standing wave and a proper reflector, were required. Besides, a gel study used to mimic the solid tumor environment exhibited that there was limited cytotoxicity when no fluid was around the cells as cavitation played an...
essential part in the selective killing. As a result, the waveform of the ultrasound used in SDT has to be considered when cytotoxicity is referred to as a metric for evaluating sonosensitizers.

**Challenges**

**Sonosensitizer screening**

There is no standard procedure to screen sonosensitizers compared with other mature targeted drugs yet. The conventional method is time- and resource-consuming. Most papers focused on the validation of the SDT effect of the photosensitizers \(^ {108}\) while a few papers verified other drugs such as non-steroidal anti-inflammatory drugs (Table 2). With the help of computer aided drug design (CADD), we can first predict the associated properties of the designed molecules in *silico* without the necessity to synthesize them. Besides, it is reasonable to simulate the interaction between oxygen and the molecules in solution to predict the ROS generating ability. Considering the oxygen-dependent nature of the SDT, conjugating a respiratory depression drug with a sonosensitizer is a reasonable strategy to relieve hypoxia and make up for the deficiency of the dissolved oxygen.

**Sonosensitizer delivery**

To avoid side effects to the maximum extent possible, healthy tissues should absorb the sonosensitizer to the lowest extent possible. Nanomedicine has been a promising way to precisely deliver drugs to tumors \(^ {109–112}\) based on the enhanced permeability and retention effect (EPR effect) but the delivery efficacy is very low and non-specific distribution is difficult to avoid. \(^ {113}\) Moreover, the excretion time of nanoparticles costs several times more than small molecules. Only a small portion of nanomedicines were successfully translated into clinical use. To come closer to clinical applications, we believe that rationally designed targeted small molecules should be mainstream in the development of sonosensitizers because of the following reasons: (i) ligand modified molecules exhibit a higher targeting ability than nanoparticles relying on the EPR effect, (ii) small molecules are capable of penetrating into deep tumor sites and (iii) small molecules with a proper log*D* exhibit better pharmacokinetics. All these features determine that small molecules are feasible to be approved by the regulatory agency.

**Safety**

From the *in vitro* data we have determined that the SDT requires a higher concentration of drugs to achieve a comparable cytotoxicity by PDT. \(^ {102}\) So, the toxicity of the high dose of sonosensitizer *in vivo* is a big concern. There is still limited research studying the dose-dependent toxicity of sonosensitizers but it is essential because we cannot simply believe that the PSs or other clinical approved drugs are also safe when they are used as sonosensitizers at a much higher dose. Another safety concern is the intensity of ultrasound. We cannot ignore the attenuations of ultrasound as it travels through tissues. It is still hard to evaluate the accurate ultrasound focus intensity *in vivo*, though it is not hard to achieve *in vitro* by using a hydrophone. As a result, this will raise the question of whether the ultrasound intensity is enough to excite the sonosensitizer *in vivo* to achieve therapeutic effects. In order to improve the treatment efficacy, the sound intensity should be well adjusted to meet the treatment requirements of tumors in different tissues. It is highly recommended that the acoustic pressure should also be reported for the purpose of evaluating the bioeffects of the ultrasound. At the same time, the tolerance of ultrasound in different healthy organs has to be taken into consideration to avoid undesirable damage.

**Effectiveness of SDT**

Strictly, current clinical data on SDT has not provided convincing evidence for the effectiveness of SDT. A more common conclusion is that ultrasound could enhance the treatment effect of PDT after patients received light exposure. \(^ {114}\) A lot of pre-clinical research has demonstrated that photo-sonodynamic therapy or sono-photodynamic therapy surpassed monotherapy but the mechanism behind this is far from being elucidated. \(^ {20}\) Plenty of tumor bearing mice have been cured by SDT, but we are eager to see its effect on bigger animals and even on humans.

**Conclusions**

Sonodynamic therapy holds great potential for the non-invasive treatment of tumors. However, the lack of effective sonosensitizers hinders its progress to clinical trials. When we optimize sonosensitizers, the ROS generation ability, pharmacokinetics and even the match with the unique ultrasound parameters are affected (Fig. 9). There still is no established relationship between the molecular chemical structure and the ROS generating ability, as well as the ultrasound parameters. Moreover, the ultrasound–cell interactions under exposure to distinctive molecules can be quite diverse. For clinical cancer treatment, a

| Table 2: Clinical and pre-clinical sonosensitizers and the matched ultrasound parameters |
|------------------------------------|----------------|-----------------|----------------|-----------------|-----------------|
| **Sonosensitizer** | **Tumor** | **Frequency** | **Sound intensity** | **Time** | **Treatment cycles** | **Dose** | **Ref.** |
| Porphyrin | SF1 | S180 | 1 MHz | 1.2 W cm\(^{-2}\) | 3 min | 1 | 20 mg kg\(^{-1}\) (i.p.) | 99 |
| | ATX-70 | Colon adenocarcinoma | 2 MHz | 3 W cm\(^{-2}\) | 15 min | 1 | 2.5 mg kg\(^{-1}\) (i.v.) | 100 |
| | DVDMS | S180 | 1.9 MHz | 4 W | 3 min | 3 | 2 mg kg\(^{-1}\) (i.v.) | 101 and 102 |
| | PpIX | Oral squamous cell carcinoma | 1 MHz | 0.89 W cm\(^{-2}\) | 15 min | — | — | 103 |
| | DCPH-P-Na | MKN-45 | 1 MHz | 1–2 W cm\(^{-2}\) | 10 min | 1 | 144 μg/kg (i.v.) | 23 |
| | DEG | MKN-74 | 1 MHz | 2 W cm\(^{-2}\) | 10 min | 6 | 1 mg kg\(^{-1}\) | 104 |
| Phthalocyanine | AlPcTS | Colon adenocarcinoma | 1.92 MHz | 3 W cm\(^{-2}\) | 15 min | 1 | 2.5 mg kg\(^{-1}\) | 105 |
| | Cynamine | IR780 | Breast cancer | 1 MHz | 2 W cm\(^{-2}\) | 4 min | 1 | 80 μg (i.t.) | 106 |
| | Xanthene | Bengal Rose | Glioma | 1 MHz | 25 W cm\(^{-2}\) | 5 min | 1 | 50 mg kg\(^{-1}\) (i.v.) | 107 |
combination of SDT and other modalities, including chemotherapy and immunotherapy, could enhance the therapeutic effects of monotherapy. We believe that elucidating the fundamental principles of SDT and the actual synergistic mechanism of ultrasound and drug therapy could pave the way for the final clinical translation of SDT.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

This contribution was financially supported by the National Project for Research and Development of Major Scientific Instruments (No. 81727803), National Key Research and Development Program of China (No. 2016YFA0201400), State Key Program of National Natural Science of China (No. 81930047), Projects of International Cooperation and Exchanges NSFC-PSF (No. 31961143003), Beijing Natural Science Foundation, Haidian, original innovation joint fund (No. 17L20170), and Foundation for Innovative Research Groups of the National Natural Science Foundation of China (No. 81421004).

References

8 A. P. McHale; J. F. Callan; N. Nomikou; C. Fowley and B. Callan, Sonodynamic Therapy: Concept, Mechanism and Application to Cancer Treatment, Therapeutic Ultrasound, 2016, pp. 429–450.
18 Y. You, X. Liang, T. Yin, M. Chen, C. Qiu, C. Gao, X. Wang, Y. Mao, E. Qu and Z. Dai, Porphyrin-grafted lipid microbubbles for the enhanced efficacy of photodynamic
therapy in prostate cancer through ultrasound-controlled in situ accumulation, *Theranostics*, 2018, 8(6), 1665.


Review

Complex-Based Nanosonosensitizers for Deep-Tissue Tumor Theranostics by Noninvasive Sonodynamic Therapy, Small, 2019, 15(5), e1804028.


60 X. Liang, X. Li, L. Jing, X. Yue and Z. Dai, Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy, Biomaterials, 2014, 35(24), 6379–6388.


75 M. A. Biel; A. M. Gillenwater; D. M. Cognetti; J. M. Johnson; A. Argiris and M. Tahara, A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC), American Society of Clinical Oncology, 2019.

Materials Chemistry Frontiers

Review


H. Tsuru, H. Shibaguchi, M. Kuroki, Y. Yamashita and M. Kuroki, Tumor growth inhibition by sonodynamic...


